✦ LIBER ✦

THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER

✍ Scribed by Smith, David C.; Pienta, Kenneth J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Issues with the Use of Prostate-Specific

✍ Don W.W. Newling 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 232 KB

SURROGATE END POINT FOR PROSTATE CANCER

✍ DAMICO, A; MOUL, J; CARROLL, P; SUN, L; LUBECK, D; CHEN, M 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 86 KB

SURVIVAL OF PATIENTS WITH HORMONE REFRAC

✍ OEFELEIN, MICHAEL G.; AGARWAL, PIYUSH K.; RESNICK, MARTIN I. 📂 Article 📅 2004 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 82 KB

Effect of Prednisone on Prostate-Specifi

✍ Sartor, O.; Weinberger, M.; Moore, A.; Li, A.; Figg, W.D. 📂 Article 📅 1999 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 108 KB

Effect of prednisone on prostate-specifi

✍ Oliver Sartor; Maribeth Weinberger; Andrea Moore; Ailing Li; William D Figg 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Prostate-Specific Antigen Response to Wi

✍ Wehbe, Tarek W.; Stein, Barry S.; Akerley, Wallace L. 📂 Article 📅 1997 🏛 Mayo Clinic 🌐 English ⚖ 393 KB